Pulmonary Hypertension Association Rated Four-Star Charity

Pulmonary Hypertension Association Rated Four-Star Charity

PHAThe Pulmonary Hypertension Association (PHA) has been rated a four-star organization for the 12th consecutive year by Charity Navigator. The evaluator of U.S. charities awarded the rating to PHA due to its good governance adherence, sound fiscal management, accountability commitment and transparency, company best practices, and a fiscally responsible mission.

Charity Navigator works as a system that evaluates charity organizations throughout the country in order to offer donors and investors information that may help them make a decision on donating or provide them with more confidence in making charitable choices. PHA’s work relies on donations in order to support patients who suffer from pulmonary hypertension (PH) and research projects to improve the disease’s treatment.

“PHA relies on donors to fund patient and caregiver support; early diagnosis awareness; medical education; specialty care services; and research to find ways to prevent and cure PH,” explained the president and CEO of PHA, Rino Aldrighetti, in a press release. “This commitment carries over into how we conduct business, leaving no doubt that we are a charity worth supporting.”

The Charity Navigator has announced that the PHA’s four-star rating, which has been granted for 12 years in a row, is the result of the organization meet a set criteria mainly associated with transparency and commitment. In addition, the position puts the charity organization within the 1% top charities evaluated by Charity Navigator, meaning that the association outperformed the vast majority of American charities.

“As the nonprofit sector continues to grow at an unprecedented pace, savvy donors are demanding more accountability, transparency and quantifiable results from the charities they choose to support with their hard-earned dollars,” added the founder and chairman of the Board of Charity Navigator, John P. Dugan.

[adrotate group=”4″]

PH is a rare lung disease that also affects the normal functioning of the heart, eventually leading to cardiac failure. As a debilitating disease for which there is currently no cure, the average survival rate is about 2.8 years after diagnosis. PHA’s efforts are focused not only on improving treatment and finding a cure for the disease, but also on helping patients deal with the diagnosis and the daily struggle.

Recently, the association expressed its full support for the Patients’ Access to Treatments Act (PATA), which was recently introduced in the House of Representatives by Lois Capps (D-CA) and David B. McKinley (R-WV). The bi-partisan legislation’s purpose is to limit cost-sharing requirements for medications included in healthcare plans’ specialty tier so that life-saving medications can be easily accessible by significantly decreasing patients’ out-of-pocket expenses.

Leave a Comment

Your email address will not be published. Required fields are marked *